2023
Transcatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry
Dallan L, Tang G, Forrest J, Reardon M, Szeto W, Kodali S, Baeza C, Eisenberg R, Attizzani G. Transcatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry. Circulation Cardiovascular Interventions 2023, 16: e012623. PMID: 36943929, PMCID: PMC10022658, DOI: 10.1161/circinterventions.122.012623.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementCardiology Transcatheter Valve Therapy RegistryThoracic Surgeons/American CollegeTranscatheter Valve Therapy RegistryValve replacementAortic stenosisAmerican CollegeMultivariable Cox proportional hazards regression modelsAnnulus sizeCox proportional hazards regression modelProportional hazards regression modelsAortic valve reinterventionTricuspid aortic stenosisReal-world registrySevere aortic stenosisBetter clinical outcomesTreatment of patientsHazards regression modelsComputed tomography angiographyLarge annulusValve reinterventionCause mortalityReadmission ratesValve procedures
2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV